As of 2024-12-15, the EV/EBITDA ratio of Talis Biomedical Corp (TLIS) is 0.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TLIS's latest enterprise value is -5.68 mil USD. TLIS's TTM EBITDA according to its financial statements is -41.45 mil USD. Dividing these 2 quantities gives us the above TLIS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.2x - 20.7x | 19.0x |
| Forward P/E multiples | 20.3x - 21.0x | 20.6x |
| Fair Price | (52.86) - 5.22 | (26.89) |
| Upside | -1306.9% - 19.3% | -713.9% |
| Date | EV/EBITDA |
| 2024-12-13 | 0.93 |
| 2024-12-12 | 0.90 |
| 2024-12-11 | 0.90 |
| 2024-12-10 | 0.95 |
| 2024-12-09 | 0.93 |
| 2024-12-06 | 0.90 |
| 2024-12-05 | 0.90 |
| 2024-12-04 | 0.91 |
| 2024-12-03 | 0.92 |
| 2024-12-02 | 0.91 |
| 2024-11-29 | 0.92 |
| 2024-11-27 | 0.89 |
| 2024-11-26 | 0.92 |
| 2024-11-25 | 0.94 |
| 2024-11-22 | 0.94 |
| 2024-11-21 | 0.94 |
| 2024-11-20 | 0.93 |
| 2024-11-19 | 0.93 |
| 2024-11-18 | 0.92 |
| 2024-11-15 | 0.89 |
| 2024-11-14 | 0.93 |
| 2024-11-13 | 0.92 |
| 2024-11-12 | 0.92 |
| 2024-11-11 | 0.91 |
| 2024-11-08 | 0.90 |
| 2024-11-07 | 0.90 |
| 2024-11-06 | 0.92 |
| 2024-11-05 | 0.95 |
| 2024-11-04 | 0.93 |
| 2024-11-01 | 0.93 |
| 2024-10-31 | 0.93 |
| 2024-10-30 | 0.92 |
| 2024-10-29 | 0.95 |
| 2024-10-28 | 0.98 |
| 2024-10-25 | 0.94 |
| 2024-10-24 | 0.94 |
| 2024-10-23 | 0.94 |
| 2024-10-22 | 0.94 |
| 2024-10-21 | 0.94 |
| 2024-10-18 | 0.89 |
| 2024-10-17 | 0.91 |
| 2024-10-16 | 0.92 |
| 2024-10-15 | 0.92 |
| 2024-10-14 | 0.94 |
| 2024-10-11 | 0.93 |
| 2024-10-10 | 0.94 |
| 2024-10-09 | 0.93 |
| 2024-10-08 | 0.93 |
| 2024-10-07 | 0.92 |
| 2024-10-04 | 0.91 |